Journal article icon

Journal article

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

Abstract:

Objectives: Evaluate the efficacy of guselkumab for the treatment of active psoriatic arthritis (PsA) utilizing composite indices.

Methods: Data were pooled from the Phase 3 DISCOVER-1 (N=381) and DISCOVER-2 (N=739) studies. In both studies, patients were randomized 1:1:1 to subcutaneous guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at Week 0, Week 4, then Q8W; or placebo Q4W with crossover to guselkumab 100 mg Q4W at Week 24. Composite ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/rheumatology/keac375

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Botnar Research Centre
Role:
Author
ORCID:
0000-0002-4756-663X
Publisher:
Oxford University Press
Journal:
Rheumatology More from this journal
Volume:
62
Issue:
2
Pages:
606–616
Publication date:
2022-06-29
Acceptance date:
2022-06-18
DOI:
EISSN:
1462-0332
ISSN:
1462-0324
Language:
English
Keywords:
Pubs id:
1264334
Local pid:
pubs:1264334
Deposit date:
2022-06-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP